Human papillomavirus (HPV)-associated cancers disproportionately affect those infected with HIV despite effective combination antiretroviral therapy (cART). The primary aim of this study was to quantify HPV16 and HPV52 E6-specific interferon (IFN)-c enzyme-linked immunospot (ELISPOT) T-cell responses, a correlate of protective immunity, in the first year following cART initiation and subsequently in those patients with suboptimal (sIR) and optimal (oIR) immune reconstitution.
Introduction
Effective combination antiretroviral therapy (cART) has led to a dramatic increase in life expectancy among individuals living with HIV [1, 2] . While the frequency of opportunistic infections has reduced significantly among those living with HIV, the incidence of human papillomavirus (HPV)-associated diseases, including cancers, is increasing [3, 4] . This is consistent with the rising burden of HPV-associated cancers even among those without HIV infection [5, 6] . When compared with the general population in the USA, those living with HIV had a 38-fold higher risk of developing anal cancer and a 2.7-fold increased risk of invasive cervical cancer [7] . In addition, HPV-associated oral cancer is also 3-fold more common in HIV-positive men than in the general population [8] . It is estimated that 15% of all new cancer diagnoses among those living with HIV can be attributed to HPV infection [7] compared with 4.8% among the general population [9] .
Cellular immune responses are central in balancing health and disease states associated with HPV infection. The role of cellular immune responses to HPV has been demonstrated in immune-histological studies where the regression of cervical intraepithelial neoplasia and genital warts has been associated with an influx of CD4 T cells, CD8 cytotoxic T cells and macrophages [10, 11] , while HPV-specific T-cell responses to HPV E6 antigens have been consistently shown to correlate with virological clearance or clinical regression of HPV-associated diseases [12] [13] [14] [15] . This in turn has been exploited in the development of therapeutic vaccines where immunological responses to E6 were found to correlate with clinical outcomes [16] [17] [18] . Therefore, the presence or detection of a systemic HPV E-6 specific responses may identify those who are able to mount a protective cellular immune response against persistent HPV infection and it's related diseases. The higher prevalence of HPV infection [19] and cancers among individuals living with HIV suggests that, despite apparently optimal immune reconstitution as assessed by CD4 T-cell count and viral suppression, a protective immunological response against oncogenic HPV may either never or inadequately be mounted. A better understanding of the natural history of HPV infection and functional reconstitution of HPV-specific immunity in those with living with HIV would inform prevention and treatment strategies against HPV-associated diseases.
We therefore explored the association of HPV immunity with CD4 T-cell reconstitution among HIV-infected individuals receiving suppressive cART. Our primary aim was to define immunological correlates of HPV16 and HPV52 E6-specific immune responses following cART initiation. We also explored the prevalence of and risk factors associated with HPV DNA detection in the anogenital tract and oral cavity among this multi-ethnic Asian HIV-infected cohort receiving suppressive cART.
Methods

Study population
Two cohorts of HIV-infected patients (longitudinal and cross-sectional) were recruited from the Infectious Diseases Unit (IDU), University Malaya Medical Centre (UMMC). The longitudinal cohort (n = 27) comprised patients commencing cART (t = 0 weeks) and were followed up for 48 weeks (t = 12, 24 and 48 weeks). The inclusion criteria were: men or women > 18 years old, na€ ıve to cART, who had no acute illness and were not pregnant at recruitment. The crosssectional cohort consisted of patients with suboptimal (sIR) and optimal (oIR) immune recovery. The inclusion criteria were: men > 18 years old, receiving cART for a minimum of 2 years, with a CD4 T-cell count persistently < 350 cells/lL (sIR) or > 500 cells/lL (oIR) on suppressive (HIV RNA < 50 copies/mL) cART. HIV-negative controls were recruited from a local community-based clinic. Samples of 40 mL of blood, anal swab and oral rinse were collected. Peripheral blood mononuclear cells (PBMCs) were isolated for interferon-c (IFN-c) enzyme-linked immunospot (ELISPOT) assay and immunophenotyping. Clinical and detailed sociodemographic parameters were extracted from medical records and a self-administered questionnaire. All participants provided written informed consent and this study was approved by the UMMC ethics review board (Medical Ethics Committee Reference: 865.18).
HPV DNA testing
Anal swabs were collected using a pre-moistened cervical brush (Hybribio Limited, Hong Kong, China). The oral rinse was obtained by gargling with 10 mL of (Listerine â , Johnson & Johnson Sdn Bhd, Petaling Jaya, Malaysia) mouthwash. DNA was extracted from both anal and oral samples, and HPV DNA typing was performed using the Hybribio Rapid GenoArray test kit (Hybribio Limited) [20] . This kit detects 21 HPV genotypes, including 13 high-risk (HR) genotypes (16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, 59 and 68), six low-risk genotypes (6, 11, 42, 43, 44 and CP8304 [81] ), and two probable high-risk types (53 and 66). The tests were performed according to the manufacturer's protocol [20] . Briefly, the extracted DNA was subjected to polymerase chain reaction (PCR) amplification using HPV L1 consensus PCR primers. The PCR products were subsequently added to a probed membrane followed by flow-through hybridization and colourimetric reaction for detection of amplified HPV DNA.
Anal cytology
The anal cytological samples were collected without anoscopic guidance using the pre-moistened brush into ThinPrep (Hologic Inc., Marlborough, USA) liquid-based specimen collection vials and Papanicolaou stained. All slides were read by a single experienced pathologist, utilizing the Bethesda System 2001 criteria and terminology [21] .
IFN-c ELISPOT
IFN-c-producing HPV-specific T cells were quantified using ELISPOT as previously described [13, 22, 23] Further antibody incubations and development of the ELISPOT were performed as described [13] . The measured HPV E6-specific IFN-c responses were from a combination of CD4 and/or CD8 T cells against type HPV16 or HPV52. Spots were counted with a fully automated computer-assisted video-imaging analysis system (CTL ImmunoSpot â , Cellular Technology Ltd, Shaker Heights, Ohio, USA). Specific spots were calculated by subtracting the mean number of spots plus two times the standard deviation of the medium control from the mean number of spots in experimental wells. Antigen-specific T-cell frequencies were considered to be positive when specific T-cell frequencies were > 1/10 4 PBMCs.
T-cell immunophenotyping by flow cytometry
Briefly, 1 9 10 6 thawed PBMCs were stained in two sepa- 
Data analysis
Clinical and immunological characteristics were compared using the Mann-Whitney U-test and v 2 or Fisher's exact test. Logistic regression analysis was used to assess immunological factors associated with HPV carriage and HPV-specific responses. Covariates with P < 0.25 and well-established risk factors were included in the multivariate model where a P-value of < 0.05 was considered significant. Statistical analyses were performed using SPSS STATISTICS version 22 (IBM, New York, USA).
Results
Patient characteristics
In total, 94 HIV-infected patients were recruited, 27 in the longitudinal arm and 67 in the cross-sectional arm, and 29 HIV-negative controls.
In the cross-sectional cohort, 32 patients displayed sIR while 35 had oIR. The median age was 41 [interquartile range (IQR) 39-48] years, with 40 of 63 patients (63.5%) being smokers, 16 of 50 (32.0%) circumcised and 27 of 64 (42.2%) men who have sex with men (MSM) ( Table 1 ). The median duration on suppressive cART was 5 (IQR 3-9) years (Table 2) . Age, smoking history, circumcision rate, and sexual orientation were not significantly different between those with sIR and oIR (Table 1 ), but baseline CD4 T-cell count was significantly higher in those with oIR compared with those with sIR [190 (IQR 66-314) vs. 28 (IQR 10-59) cells/lL; P < 0.001] ( Table 2 ).
In the longitudinal cohort, the median age was 35 (IQR 30-41) years, with all other parameters including smoking history, circumcision rate and sexual orientation being comparable to those in the cross-sectional cohort ( Table 1) . The median baseline CD4 T-cell count was 221 (IQR 63-319) cells/lL (Table 2) . Of interest, comparison of T-cell subsets between heterosexuals and homosexuals demonstrated a significantly higher proportion of activated CD8 T cells (CD8 + CD38 + HLA-DR + )
among the homosexuals. However, there were no differences observed in the proportions of T-regulatory cells, senescent CD4 and CD8 T cells or activated CD4 T cells.
In the HIV-negative controls, the median age was 39 (IQR 29-53) years, comparable to that of the HIV-positive patients (P = 0.314). Higher percentages of individuals were circumcised (17 of 28; 60.7%; P = 0.014) and, notably, heterosexual (24 of 25; 96.0%) compared with the HIV-infected individuals (Table 1) .
Prevalence and risk factors associated with HPV DNA detection
Overall, 25 of 44 (56.8%) and 7 of 51 (13.7%) of the cross-sectional cohort had HPV DNA detected in the anal and oral cavities, respectively, with no significant differences between the sIR and oIR groups (P = 0.604 and P = 0.432, respectively) ( Table 3 ). In anal samples with detectable HPV DNA, 17 of 25 (68.0%) had two or more HPV types, with 21 of 25 (84.0%) having an HR HPV. HPV16 and HPV52 were detected in 6 of 21 (28%) and 5 In the longitudinal cohort, anal HPV DNA was detected in 19 of 26 patients (73.1%) at recruitment and this went up to 16 of 20 (80.0%) at 48 weeks, with 4 of 27 (14.8%) and 6 of 21 patients (28.6%) having HPV DNA detected in the oral cavity at the same time-points (Table 3) . Twenty-one of 24 (87.5%) of the anal samples had two or more HPV types, with 23 of 24 (95.8%) having an HR HPV type at any single time-point. The most common HR HPV types present in this cohort at any single time-point were HPV16 (45.8%) and HPV52 (37.7%). For oral samples with detectable HPV DNA, 4 of 10 (40.0%) had two or more HPV types detected at any single time-point, all of which had an HR HPV type. The most common HR HPV types present at any single timepoint were HPV18 (50.0%) and HPV16 (40.0%). No decrease in anal and oral HPV carriage was observed over the 48-week period despite cART-induced CD4 Tcell count increase.
There was a correlation between alcohol consumption and oral HPV carriage in the HIV-infected individuals (P = 0.042) and a tendency for greater HPV anal carriage with engagement in anal sex (P = 0.055) ( Table 4) . Circumcision did not influence anal HPV carriage (P = 0.255) and smoking history did not affect oral HPV carriage (P = 0.358). However, no significant risk factors were found to be independently associated with either anal or oral HPV carriage in the multivariate analysis.
In the HIV-negative controls, HPV DNA was detected in the anal canal in 1 of 16 individuals (6.3%), which was significantly lower than in the HIV-infected cohorts (P < 0.001), while detection in the oral cavity was comparable at 3 of 29 (10.3%) (P = 0.337).
Correlation between anal cytology and HPV DNA detection
In the cross-sectional cohort, only 44 of 67 samples had sufficient cells for cytological assessment. In the comparison of the sIR and oIR groups, there was no difference in those with cytology grade higher or equal to atypical squamous cells of undetermined significance (ASC-US) (38.9% versus 25.0%, respectively; P = 0.358). While the presence of anal HPV DNA carriage was positively associated with cytology grade higher or equal to ASC-US (P = 0.001), no association between multiple HPV types or the presence of HR-HPV was observed. (P = 0.13 and P = 0.23, respectively). No cytological trends were observed in the longitudinal cohort. 
Immunological and clinical correlates of HPV16 and HPV52 E6-specific responses
Overall, 12 of 91 patients (13.2%) in the HIV-infected cohort exhibited HPV16 and HPV52 E6-specific responses (Table 3 ) compared with 2 of 28 individuals (7.1%) in the HIV-negative cohort (P = 0.385).
In the cross-sectional cohort, regardless of HPV carriage and anal cytology, significantly lower rates of HPV16 and HPV52 E6-specific responses were observed in the sIR group (2 of 32; 6.3%) compared with the oIR group (9 of 34; 26.5%) (P = 0.029) ( Table 3 ). The magnitude of the E6-specific responses between oIR (17.4; IQR 13.2-18.9) were comparable to the sIR (19.3; IQR 15.2-23.8) group (P = 0.637). The presence of HPV16 and/or HPV52 at anal and/or oral sites at the time of recruitment did not correspond to the HPV16 and HPV52 E6-specific immunity detected (P = 0.339). Baseline CD4 T-cell counts and duration on cART were not different in individuals with and without HPV16 and HPV52 E6-specific responses (P = 0.282 and 0.965, respectively). However, individuals with higher CD4 T-cell counts at recruitment had a significantly greater magnitude of HPV16 and HPV52 E6-specific responses (P = 0.028). While there were significant differences in the E6-specific responses between the oIR and sIR groups, responses to memory recall mix (MRM) only trended towards significance (P = 0.569) ( Table 3 ).
In the longitudinal cohort (n = 25), only one patient displayed HPV16 and HPV52 E6-specific responses at weeks 12 and 24 after cART initiation. This individual had HPV52 detected in the anal canal at weeks 12 and 24. While the immune responses to E6 peptides were barely detectable, approximately 50% of the patients mounted a response to MRM despite the low CD4 T-cell counts (Table 3 ).
In the analysis of immune correlates of HPV16 and HPV52 E6-specific responses in cART-treated HIVinfected individuals, the data for the cross-sectional and longitudinal (week 48) cohorts were combined (Table 5 ). In the univariate analysis, differences in T-cell maturational subsets (na€ ıve, CM, EM and TdEM) were not associated with HPV16 and HPV52 E6-specific responses. However, higher CD4 T-cell activation (P = 0.030) was significantly associated with the lack of HPV16 and HPV52 E6-specific responses, with only a tendency for higher CD8 T-cell activation exhibiting a similar trend (P = 0.067). Neither the proportion of CD4 T-regulatory CMV, cytomegalovirus; HR HPV, high-risk HPV genotype; oIR, optimal immunological responder; MRM, memory recall mix; sIR, suboptimal immunological responder.
cells (P = 0.959) nor the proportion of senescent CD4 T cells (P = 0.718) and CD8 T cells (P = 0.433) was associated with HPV16 and HPV52 E6-specific responses. In addition to CD4 T-cell counts at recruitment (P = 0.008), there was a tendency for patients with a lower CD4:CD8 T-cell ratio (P = 0.072) to fail to mount a HPV16 and HPV52 E6-specific response (Table 5 ).
In the multivariate analysis, none of the immunological parameters were independently associated with HPV16 and HPV52 E6-specific immune responses.
Discussion
To date, this is the largest study to have assessed the correlates of systemic HPV-specific immune responses to immune recovery following cART among those with HIV infection. We quantified HPV-specific immunity during the initial phase of immune recovery following cART and subsequently in patients with sIR and oIR. We showed that HPV-specific immune responses were rarely detected during the first year following cART initiation but in individuals on cART for a longer duration, an optimal immune recovery of > 500 cells/lL was associated with significantly higher frequencies of HPV-specific responses compared with individuals with suboptimal recovery (< 350 cells/lL). When assessing the immunological correlates of HPV-specific responses, only higher CD4 T-cell counts and lower CD4 T-cell activation were found to be associated with HPV-specific responses.
The anal and oral HPV carriage rates in our HIVinfected cohort of 64.1% and 18.1%, respectively, are consistent with the high prevalence of HPV infection reported among HIV-infected individuals (42-96% for anal HPV and 9.6-38.5% oral HPV). These studies also demonstrated that HPV16 and HPV52 are the most common HPV types [26] [27] [28] [29] . The consistently higher prevalence of HR HPV observed globally, despite effective cART and CD4 T-cell recovery, point towards an inadequate immune-mediated resolution of and protection against HPV infection. We investigated HPV-specific immune responses during the different phases of immune recovery following cART initiation. In the longitudinal cohort, only one of 25 patients exhibited HPV-specific responses within the first 48 weeks of suppressive cART. In contrast, higher frequencies of HPV-specific responses were detected in the cross-sectional cohort with a median duration of 5 years on cART. More strikingly, individuals in the oIR group had a significantly higher rate of HPV-specific response (26.5%) compared with the sIR group (6.3%). The lack of antigen-specific responses against pathogens during early recovery has previously been observed in other HIV coinfections [30, 31] . It was therefore not unexpected for HPV-specific responses to be infrequently detected during the first year of treatment. Furthermore, HPV is exclusively epitheliotrophic, where the majority of antigenspecific immune cells reside locally (reviewed in [32] ) with low but detectable levels of circulating HPV-specific T cells. The recovering immune system during cART initiation is also challenged by a larger load of other systemic antigens including human herpes viruses [33] , as evidenced by a detectable MRM response in nearly half of the longitudinal cohort, 12 weeks after commencing cART. Taken together, the lack of HPV-specific responses in the early phase of CD4 T-cell recovery and, subsequently, increased responses seen in oIR imply that a specific threshold of CD4 T cells is required before HPVspecific immunity can be detected. The concept of immune competence as assessed by CD4 T-cell counts and its association with virus-specific cellular immunity has also been observed in HIV/hepatitis B virus-and cytomegalovirus (CMV)-coinfected individuals [30, 34] . Alternatively, the lack of HPV-specific responses in the early phase of immune recovery could be driven by the loss of memory-specific cells as a result of greater turnover, as we observed a significant inverse correlation between CD4 T-cell activation and HPV-specific responses in this cohort.
In our cohort, neither the extent of immune recovery nor the development of HPV16 and HPV52 E6-specific responses was associated with differences in HPV carriage or abnormal anal cytology. This is not surprising, as histological outcomes (biopsies) have been shown to correlate better to the immunological markers compared with virological or cytological outcomes [13] , particularly as this study was limited by its small numbers.
The largest study to date identifying HPV16 E6-specific responses was conducted in a mixed HIV-infected/negative population of MSM using a flow cytometry-based assay [24] . In that study, 50% of subjects displayed HPV16 E6-specific responses, but this response did not show any correlations with age, HIV status, or anal HPV16 status. However, a trend between recent anal high-grade squamous intraepithelial lesion (HSIL) regression and systemic E6-specific CD4 T-cell response was demonstrated, confirming the superiority of tissue biopsies over HPV DNA detection as a surrogate marker for clinical outcomes.
The observed rate of HPV16 and HPV52 E6-specific response among the HIV-negative controls (7.1%) was lower than the expected value of 30À50%. The discrepancy could be explained by differences in the study populations. Historically, studies demonstrating high rates of protective immunity associated with E6-specific responses have been predominantly conducted in women with cervical disease with regressing lesions or low-grade disease that did not progress to high-grade lesions [12] [13] [14] [15] . In contrast, our controls were healthy men with low anal HPV carriage rates.
The strength of the study is its well-characterized clinical population and correlating it to immunological outcomes in HIV-infected individuals. It also utilized a sensitive T-cell assay (IFN-c ELISPOT) that has been validated and used in various populations [12, 13, 22, 23] to detect low levels of antigen-specific immunity. A major limitation of this assay is that IFN-c was the only parameter measured, discounting the effects of other regulatory cytokines. Other limitations of the study include small sample numbers in the longitudinal cohort and the lack of immunological correlates to long-term clinical outcomes.
Despite effective viral suppression on cART, one-third of patients will not achieve optimal CD4 T-cell recovery, especially in those starting treatment late [35, 36] . They are also particularly susceptible to non-AIDS-associated comorbidities [37, 38] . This study has demonstrated that those with suboptimal immune recovery also lack HPV protective immunity and are possibly at greater risk of developing serious HPV-associated diseases. We propose that this group should be considered for more intensive screening and should be encouraged to consider HPV vaccination. There is good evidence to suggest that HPV vaccination among those who have previously received treatment for pre-malignant disease of the cervix (cervical intra-epithelial neoplasia) significantly reduced the incidence of subsequent HPV-related disease [39] . This suggests that those infected with HIV on cART exhibiting HPV-associated diseases may also potentially benefit. This is supported by immunogenicity studies among those who are HIV-infected [40] and studies that have shown that vaccinating men with a history of high-grade intraepithelial neoplasia reduces the recurrence rates by up to 50% [41] , and that this strategy is cost effective even among the HIV-infected [42] .
